PropertyValue
?:abstract
  • SARS-CoV-2, or novel coronavirus, is causing the fatal and contagious coronavirus disease-2019 (COVID-19) affecting thousands of people every single day. Researchers are continuously searching for any possible cure and/or vaccine, but no conclusive report is available till date. Like many others, we realize that a rapid, immediate, and elaborate strategy must be adopted to protect mankind. To avoid the time-loss due to clinical trials, we have performed in silico analyses on some FDA-approved drugs to combat COVID-19. We accessed information from public databases and publications, and studied the mechanism of infection of SARS-CoV-2 and the interactions of various drugs with SARS-CoV-2 proteins in silico. We found a few antivirals and antiparasitic drugs to show significant interactions with important SARS-CoV-2 proteins. Particularly Galidesivir, Remdesivir, and Pirodavir have been chosen as suggested antiviral drugs; and Proguanil, Mefloquine, and Artesunate have been chosen as suggested antiparasitic drugs based on such predicted interactions. In addition, inhibitors to prevent host-cell entry and a few supportive immune-boosters can be used in different combinations. Our study proposes a four-way attack to this fatal virus for the possible management of COVID-19 armed up with an antiviral, an antiparasitic drug, a cell-entry inhibitor, and a few supportive immune-boosters, which can be used in different combinations in different groups of people. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13337-020-00631-w) contains supplementary material, which is available to authorized users.
is ?:annotates of
?:creator
?:doi
  • 10.1007/s13337-020-00631-w
?:doi
?:journal
  • Virusdisease
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/ba0a04ae6dd771f9735ecf38893e3f9db4047a50.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7657379.xml.json
?:pmcid
?:pmid
?:pmid
  • 33200085.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Combinatorial therapeutic trial plans for COVID-19 treatment armed up with antiviral, antiparasitic, cell-entry inhibitor, and immune-boosters
?:type
?:year
  • 2020-11-11

Metadata

Anon_0  
expand all